COMPANY

OncoC4

Keywords: oncology neurology cancer Non Small Cell Lung Cancer Ovarian Cancer High Grade Serous Adenocarcinoma of Ovary Primary Peritoneal Carcinoma Fallopian Tube Cancer Gastric Cancer Esophageal Cancer Cervical Cancer Metastatic Melanoma Metastatic Head and Neck Carcinoma Metastatic Renal Cell Carcinoma Metastatic Colorectal Cancer Sarcomas Metastatic Prostate Cancer Small Cell Lung Cancer Metastatic Breast Cancer Pancreas Cancer Gastroesophageal Junction Adenocarcinoma Adenoid Cystic Carcinoma Salivary Gland Cancer Urothelial Carcinoma Melanoma Head and Neck Squamous Cell Carcinoma Endometrial Cancer Renal Cell Carcinoma Bladder Cancer Gastroesophageal-junction Cancer Colorectal Cancer Anal Cancer Hepatocellular Carcinoma Bile Duct Cancer Metastatic Castration-resistant Prostate Cancer ONC-392 ONC-841 AI-061 ONC-783 Gotistobart AI-081

Location: Rockville, MD · source · Oct 15, 2026

Profile checked Oct 10, 2026

10Trials (company is sponsor)2NIH grants

Raises and deals from press releases

Raise Series B · about $50M · announced Oct 2, 2025 Company release ↗
Source quote
- Oct 2, 2025 · Company release ↗
  “ROCKVILLE, Md., Oct. 02, 2025 — OncoC4, Inc. a clinical-stage biotechnology company, today announced the recent closing of a Series B financing round of nearly $50 million.”

From the company’s own releases; this list is partial. All raises and deals

Timeline

Aug 10, 2026 Trial start Phase 1: Safety, Pharmacokinetics (PK), and Efficacy of ONC-783 in Advanced Solid Tumors source ↗
Jul 28, 2026 Trial start Phase 3: Gotistobart Long Term Extension (LTE) Study source ↗
Oct 2, 2025 Raise Series B · about $50M source ↗
Mar 26, 2025 Trial start Phase 1/Phase 2: Safety, Pharmacokinetics, and Efficacy of AI-081, a Bispecific Antibody for PD-1 And VEGF in Advanced Solid Tumors source ↗
Aug 23, 2024 Trial start Phase 1: Safety, Pharmacokinetics (PK), and Efficacy of ONC 841 in Advanced Solid Tumors source ↗
Dec 11, 2023 Trial start Phase 1/Phase 2: ONC-392 Plus Lutetium Lu 177 Vipivotide Tetraxetan in Patients With mCRPC source ↗
Jul 11, 2023 Trial start Phase 1: Safety, PK and Efficacy of AI-061 in Advanced Solid Tumors source ↗
Jun 28, 2023 Trial start Phase 3: ONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 Inhibitors source ↗
Dec 22, 2022 Trial start Phase 2: ONC-392 and Pembrolizumab in Platinum Resistant Ovarian Cancer source ↗
Sep 16, 2020 Trial start Phase 1/Phase 2: Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC source ↗
2024-06 Trial start Phase 1: Safety, Tolerability, Immunogenicity and Pharmacokinetics of ONC-841 source ↗

Upcoming milestones

Nov 30, 2026 (ESTIMATED) · Phase 1/Phase 2 · ONC-392 Plus Lutetium Lu 177 Vipivotide Tetraxetan in Patients With mCRPC · NCT05682443
Dec 31, 2026 (ESTIMATED) · Phase 1/Phase 2 · Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC · NCT04140526
Jun 30, 2027 (ESTIMATED) · Phase 1/Phase 2 · Safety, Pharmacokinetics, and Efficacy of AI-081, a Bispecific Antibody for PD-1 And VEGF in Advanced Solid Tumors · NCT06635785
Aug 1, 2027 (ESTIMATED) · Phase 1 · Safety, Pharmacokinetics (PK), and Efficacy of ONC-783 in Advanced Solid Tumors · NCT07408258
Aug 31, 2027 (ESTIMATED) · Phase 3 · ONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 Inhibitors · NCT05671510
Sep 30, 2027 (ESTIMATED) · Phase 1 · Safety, Pharmacokinetics (PK), and Efficacy of ONC 841 in Advanced Solid Tumors · NCT06352359
Jul 1, 2036 (ESTIMATED) · Phase 3 · Gotistobart Long Term Extension (LTE) Study · NCT07659379

Estimated primary completion per ClinicalTrials.gov. Dates move.

Clinical trials (lead sponsor) 10

Record	Title	Phase	Status	Start	Primary completion
NCT05446298	ONC-392 and Pembrolizumab in Platinum Resistant Ovarian Cancer	Phase 2	Active, not recruiting	Dec 22, 2022	Aug 30, 2026 (actual)
NCT04140526	Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC	Phase 1/Phase 2	Active, not recruiting	Sep 16, 2020	Dec 31, 2026 (estimated)
NCT05858736	Safety, PK and Efficacy of AI-061 in Advanced Solid Tumors	Phase 1	Completed	Jul 11, 2023	Jul 31, 2026 (actual)
NCT07408258	Safety, Pharmacokinetics (PK), and Efficacy of ONC-783 in Advanced Solid Tumors	Phase 1	Recruiting	Aug 10, 2026	Aug 1, 2027 (estimated)
NCT07659379	Gotistobart Long Term Extension (LTE) Study	Phase 3	Enrolling by invitation	Jul 28, 2026	Jul 1, 2036 (estimated)
NCT06635785	Safety, Pharmacokinetics, and Efficacy of AI-081, a Bispecific Antibody for PD-1 And VEGF in Advanced Solid Tumors	Phase 1/Phase 2	Recruiting	Mar 26, 2025	Jun 30, 2027 (estimated)
NCT05671510	ONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 Inhibitors	Phase 3	Active, not recruiting	Jun 28, 2023	Aug 31, 2027 (estimated)
NCT06352359	Safety, Pharmacokinetics (PK), and Efficacy of ONC 841 in Advanced Solid Tumors	Phase 1	Recruiting	Aug 23, 2024	Sep 30, 2027 (estimated)
NCT05682443	ONC-392 Plus Lutetium Lu 177 Vipivotide Tetraxetan in Patients With mCRPC	Phase 1/Phase 2	Active, not recruiting	Dec 11, 2023	Nov 30, 2026 (estimated)
NCT06219499	Safety, Tolerability, Immunogenicity and Pharmacokinetics of ONC-841	Phase 1	Withdrawn	2024-06	2025-06 (estimated)

NIH awards 2

Annual award amounts. Total $2.0M.

Apr 4, 2022 NIH award 5R44CA250824-03 FY2022: $1,000,000 awarded for that fiscal year; activity R44 (SBIR); PI ZHENG, PAN; recipient as written: ONCOC4, INC., ROCKVILLE, MD. First in Human Phase I/II clinical trial of ONC-392: P source ↗
Apr 1, 2021 NIH award 4R44CA250824-02 FY2021: $1,000,000 awarded for that fiscal year; activity R44 (SBIR); PI ZHENG, PAN; recipient as written: ONCOC4, INC., ROCKVILLE, MD. First in Human Phase I/II clinical trial of ONC-392: P source ↗